Table 2

Research agenda

General measures and prevention of SARS-CoV-2 infection
1.Large unselected registry studies to assess the course of COVID-19 in patients with rare autoimmune diseases compared with the general population.
Management of immunosuppressive or immunomodulatory drugs in patients with RMD with COVID-19
1.Large unselected registry studies to assess the risk of Janus kinase inhibitors and immunosuppressants (glucocorticoids, azathioprine, cyclosporine, cyclophosphamide, mycophenolate and tacrolimus) on a worse course of COVID-19.
2.Studies to assess the impact of other B-cell depleting strategies (eg, belimumab) on the outcome of SARS-CoV-2 infection and COVID-19 diseases course.
3.Studies to compare different disease-modifying antirheumatic drugs management strategies in the context of SARS-CoV-2 infection: unchanged, versus dose reduction versus interruption in patients with RMDs.
Vaccination of the patients with RMD
1.Studies to assess the impact of temporarily stopping medications ‘of concern’ before or after SARS-CoV-2 vaccination and supplemental (booster) dosing, in order to improve immunogenicity, and the impact of such strategies on disease activity and need of additional treatments, for example, glucocorticoids.
2.Studies to assess the impact of an additional dose as part of the initial primary SARS-CoV-2 vaccination in selected subsets of patients with RMDs, in order to improve the humoral and/or cell-mediated immunity to SARS-CoV-2 vaccines.
  • COVID-19, coronavirus disease 2019; RMDs, rheumatic and musculoskeletal diseases; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.